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Following publication of the original article \[[@CR1]\], the authors spotted an error in their paper concerning the positive rate in the right side in Table 2.

That is, 89.7 not 89., 93.5 not 93., 56.7 not 56., 75.3 not 75. and 94.0 not 94..

The original article has been corrected. The correct presentation of Table [2](#Tab1){ref-type="table"} is shown below. Table 2Positive rate of HBs antibody after HB vaccinationVaccine\
Administration routeTotal numberAge range,\
median (IQR)HBs antibodyPositive rate (%)SexTotal numberAge range,\
median (IQR)HBs antibodyPositive rate (%)Median (IQR)(+)(−)(+)(−)Bimmugen® subcutaneous51419--25,20 (19--21)84.9 (34.5--217)mIU/mL4734192.0 ^\*^Men20419--25,20 (19--21)1832189.7 ^†^Women31019--22,19 (19--19)2902093.5 ^‡^Heptavax-II® subcutaneous37319--30,20 (19--21)28.7 (5--216)mIU/mL24812566.3 ^\*^Men18019--30,20 (19--21)1027256.7 ^†^Women19319--22,19 (19--19)1464775.3 ^‡^Heptavax-II® intramuscular24719--27,20 (19--21)190 (41.6--534)mIU/mL2202789.1 ^\*^Men9719--27,20 (19--21)791881.4 ^†^Women15019--22,19 (19--20)141994.0 ^‡\*^ There was a significant difference among the Bimmugen® subcutaneous, Heptavax-II® subcutaneous, and Heptavax-II® intramuscular groups (*p* \< 0.05)^†,‡^ There were significant differences among the Bimmugen® subcutaneous, Heptavax-II® subcutaneous, and Heptavax-II® intramuscular groups in both men and women (*p* \< 0.05)
